Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-versus-host disease: a single-arm, multicentre phase 2 trial.
Fiche publication
Date publication
août 2023
Journal
EClinicalMedicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BILGER Karin, Dr DAGUINDAU Etienne
Tous les auteurs :
Malard F, Loschi M, Huynh A, Cluzeau T, Guenounou S, Legrand F, Magro L, Orvain C, Charbonnier A, Panz-Klapuch M, Desmier D, Mear JB, Cornillon J, Robin C, Daguindau E, Bilger K, Vehreschild MJGT, Chevallier P, Labussière-Wallet H, Mediavilla C, Couturier MA, Bulabois CE, Camus V, Chantepie S, Ceballos P, Gaugler B, Holler E, Doré J, Prestat E, Gasc C, Plantamura E, Mohty M
Lien Pubmed
Résumé
Failure of gastrointestinal acute graft--host disease (GI-aGvHD) to respond to steroid therapy is associated with limited further therapeutic options. We aimed to assess the safety and efficacy of the first-in-human use of the pooled allogeneic faecal microbiota, MaaT013, for the treatment of steroid-refractory GI-aGvHD.
Mots clés
Acute graft-versus-host disease, Allogeneic haematopoietic cell transplantation, Faecal microbiota transplantation, Microbiota, Prospective study
Référence
EClinicalMedicine. 2023 08;62:102111